Podcasts about Clinical

Recording after the ball drops, Dr. Griffin and Vincent Racaniello wish everyone a Happy New Year, discuss an evidence-based approach to teaching and practice medicine and reminisce on the history of vaccine development and use before their discussion about the whooping cough outbreak of 2025 in the US and falling levels of tetanus vaccination, then Dr. Griffin then deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how NY state reported the greatest number of influenza confirmed infections ever in one week during the week ending Dec 20,  where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine (JAMA) The US has seen nearly 28,000 whooping cough cases this year. Here's what you need to know (CNN) Vaccine History: Developments by Year (CHOP, Children's hospital of Philadelphia: Vaccine History) Reported Incidence of notable diseases in United States: 1952 Morbidity and Mortality Weekly Report, Vol. 1, No. 54, October 26, 1953 (CDC: Stacks) As tetanus vaccination rates decline, doctors worry about rising case numbers (nbc News) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) New York State Department of Health Confirms Most Flu Cases Ever Recorded in One Week: New York State Reports 71,123 Flu Cases This Week (NY State Department of Health) Weekly surveillance report: cliff notes (CDC FluView) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns (JAMA) RSV Immunization Frequently Asked Questions(American Academy of Pediatrics) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1284 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In today's explosive Hidden Killers breakdown, we examine the testimony that has completely reshaped the Donna Adelson trial — testimony not from police, not from experts, but from Donna's own children, whose words now carry some of the greatest weight in the courtroom. First, we turn to Wendi Adelson, whose strategy has the courtroom buzzing. While her brother Robert delivered blunt, precise answers, Wendi leaned heavily on one phrase: “I don't remember.”  Again. And again. And again. But is this selective memory a trauma response from years of family pressure, manipulation, and emotional control?  Or is it a carefully crafted shield — a strategic fog meant to protect herself, the family, and possibly Donna? Psychotherapist Shavaun Scott joins Tony Brueski to dissect Wendi's demeanor in real time, explaining how adult children of dominant or narcissistic parents often split — one breaking free and telling the truth, the other staying entangled in loyalty, denial, or fear. Jurors watch every pause. Every hesitation. Every dodge. And Shavaun breaks down exactly what those signals mean. Then we shift to Robert Adelson, whose testimony landed like a hammer. Clinical. Direct. Brutally honest. He described Donna's controlling tendencies, her intrusion into major life decisions, and her eerie lack of concern after Dan Markel's murder. His words were not defensive. They were revelatory. Defense Attorney Eric Faddis joins Tony to analyze how jurors absorb testimony when it comes straight from a defendant's own children — one distancing herself through “I don't remember,” the other stepping into the sunlight with uncomfortable truth. Is this character evidence — or is it motive crystallized? Are we watching a family fracture, or a family finally telling the truth about its own internal gravity? This isn't just testimony. This is the Adelson family dynamic cracked open in front of a jury — loyalty, fear, denial, resentment, and survival all colliding in real time. #DonnaAdelson #WendiAdelson #DanMarkel #AdelsonTrial #TrueCrime #CourtroomDrama #ShavaunScott #EricFaddis #FamilyDynamics #HiddenKillers Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

What if balance is a lie and self-care does not look anything like Instagram told you it would?  In this powerful and refreshingly honest episode of Whinypaluza, host Rebecca Greene sits down with writer, speaker, activist, and mom of eight Elisha Beach for a real conversation about motherhood, burnout, and why the idea of “having it all” is complete nonsense. Elisha shares the moments that broke her open, including a very public mommy meltdown, clinical burnout, and the pressure to put everyone else first. Together, Rebecca and Elisha unpack what self-care actually looks like in real life, how guilt sneaks in, why villages matter more than ever, and how moms can reclaim control without adding another impossible to-do list item. This is the episode every overwhelmed parent did not know they needed.Six Key Takeaways→ Balance is not real, and that is not your failureElisha explains why the idea of perfect balance sets moms up to feel like they are always falling short → Burnout does not mean weakness Clinical burnout is real and often comes from prioritizing everyone else for too long →Self-care must fit your season of life What works for one mom may not work for another, and that is exactly the point → Guilt can exist without running the show You can feel guilt without letting it dictate how you treat yourself → Your village is bigger than you think Support can include people, systems, services, and small choices that reduce mental load → You are the expert in your own life. Trusting yourself is the most important form of self-care there isMemorable Quote“Balance does not exist. You just choose what you are going to focus on and let the rest fall off for a bit.”About the GuestElisha Beach is an experienced speaker, writer, and professional mom of eight. She went viral in 2015 after sharing a raw photo of breastfeeding her daughter while on the toilet and has been unapologetically telling the truth about motherhood ever since. A former staff writer for Scary Mommy and founder of The Mom Forum, Elisha is a Certified Strategic Planner who helps moms create realistic self-care practices without guilt. She is the author of The Mom Selfcare Planner and the upcoming book Balance Is Bullsht The Truth About Motherhood and Self Care* releasing November 11, 2025. If this episode made you feel seen, heard, or even a little less alone, share it with another parent who needs permission to stop chasing perfection. Subscribe, leave a review, and remember what Rebecca reminds us every day. Laugh. Learn. Love. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's explosive Hidden Killers breakdown, we examine the testimony that has completely reshaped the Donna Adelson trial — testimony not from police, not from experts, but from Donna's own children, whose words now carry some of the greatest weight in the courtroom. First, we turn to Wendi Adelson, whose strategy has the courtroom buzzing. While her brother Robert delivered blunt, precise answers, Wendi leaned heavily on one phrase: “I don't remember.”  Again. And again. And again. But is this selective memory a trauma response from years of family pressure, manipulation, and emotional control?  Or is it a carefully crafted shield — a strategic fog meant to protect herself, the family, and possibly Donna? Psychotherapist Shavaun Scott joins Tony Brueski to dissect Wendi's demeanor in real time, explaining how adult children of dominant or narcissistic parents often split — one breaking free and telling the truth, the other staying entangled in loyalty, denial, or fear. Jurors watch every pause. Every hesitation. Every dodge. And Shavaun breaks down exactly what those signals mean. Then we shift to Robert Adelson, whose testimony landed like a hammer. Clinical. Direct. Brutally honest. He described Donna's controlling tendencies, her intrusion into major life decisions, and her eerie lack of concern after Dan Markel's murder. His words were not defensive. They were revelatory. Defense Attorney Eric Faddis joins Tony to analyze how jurors absorb testimony when it comes straight from a defendant's own children — one distancing herself through “I don't remember,” the other stepping into the sunlight with uncomfortable truth. Is this character evidence — or is it motive crystallized? Are we watching a family fracture, or a family finally telling the truth about its own internal gravity? This isn't just testimony. This is the Adelson family dynamic cracked open in front of a jury — loyalty, fear, denial, resentment, and survival all colliding in real time. #DonnaAdelson #WendiAdelson #DanMarkel #AdelsonTrial #TrueCrime #CourtroomDrama #ShavaunScott #EricFaddis #FamilyDynamics #HiddenKillers Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Dr. Carolyn Dean is a powerhouse in the field of natural and integrative medicine. With dual degrees as a medical doctor and a naturopathic doctor, Dr. Dean's unique perspective and passions have made her a pioneering voice in natural health. While she's renowned for her groundbreaking work in magnesium therapy, mineral balance, and her critique of medicine's overreliance on pharmaceuticals, that doesn't even do justice to the breadth of her expertise. Dr. Dean has written over 30 books on topics ranging from hormonal health to yeast overgrowth.   Key Takeaways To Tune In For: (02:26) – Dr. Dean's Magnesium Journey (07:15) – Magnesium's Role in the Body (12:40) – Magnesium Absorption and Testing (20:21) – Clinical vs. Lab Testing (25:07) – The Importance of Basic Nutrients (31:04) – Minerals, Toxins, and Ultra-Processed Foods   Resources talked about in this episode: Website:  http://www.drcarolyndean.com http://www.rnareset.com   Social media handles: Instagram: @drcarolyndean  YouTube: @drcarolyndean  

E se tivéssemos uma maneira de prever quais pacientes com X(T) terão recidiva precoce após a cirurgia?Foi isso que um grupo de pesquisadores chineses tentou descobrir através desse estudo publicado no American Journal of Ophthalmology em 2023.E a Dra Iluska Agra, da Universidade Federal da Bahia, estudou esse artigo para nos trazer seus principais achados de uma maneira bem didática!Vamos juntos?Link para o artigo https://www.ajo.com/article/S0002-9394(23)00094-6/abstractReferência: Wang Z, Li T, Zuo X, Liu L, Zhang T, Leng Z, Chen X, Liu H. Preoperative and Postoperative Clinical Factors in Predicting the Early Recurrence Risk of Intermittent Exotropia After Surgery. Am J Ophthalmol. 2023 Jul;251:115-125. doi: 10.1016/j.ajo.2023.02.024. Epub 2023 Mar 10. PMID: 36906096.

Ring in the New Year with a fresh episode!Join Debora, Mark, and Noah in the latest Clinical Unknown Series as they unravel a puzzling case together.Let's start the year learning! To join us live on Virtual Morning Report (VMR), sign up HERE.Download CPSolvers App hereRLRCPSOLVERS

ReferencesCell. 2018 May 31;173(6):1356-1369.e22. Clinical and Molecular Teratology 2016. Volume 106, Issue 9 September Pages 749–760Biology (Basel). 2023 Mar 30;12(4):527. dInt J Mol Sci. 2021 Feb 22;22(4):2158. Anderson and Squire. 1971. I've Seen all Good People. Yes.https://music.youtube.com/watch?v=WfgPEh2J9aI&si=cTVabGFH5JYqN-EjMozart , WA. 1788. Symphony 40 in G Minor K550.https://music.youtube.com/watch?v=z_4jMxbwmVc&si=0n5dbpCqtE4WjYFw

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some fascinating updates that are shaping the future of medicine and healthcare.Let's start with a groundbreaking development in cancer treatment. Researchers have announced significant progress in a novel therapy targeting a specific mutation often found in non-small cell lung cancer. This mutation, known as EGFR exon 20 insertion, has historically been resistant to standard treatments. The new therapy employs a targeted approach that precisely inhibits the mutant protein while sparing normal cells. Early-phase clinical trials have shown promising results, with substantial tumor shrinkage observed in participants. This could potentially redefine treatment protocols for patients who previously had limited options and improve their overall survival rates. As the study progresses into later phases, the industry is watching closely to see if these initial successes translate into long-term benefits.In another significant development, we're seeing advancements in gene therapy for inherited retinal diseases. A recent study has highlighted a novel gene-editing technique that promises to restore vision in patients with certain genetic forms of blindness. By utilizing CRISPR-Cas9 technology, scientists have been able to directly correct mutations in retinal cells. The preclinical models have shown restored function and improved visual responses, paving the way for human trials. This breakthrough is not just a beacon of hope for those affected by genetic blindness but also underscores the transformative potential of gene-editing technologies in treating complex diseases.Moving on to regulatory news, there's an update on new drug approvals that could have widespread implications for public health. The FDA has recently approved a first-in-class drug for the treatment of severe migraines. This medication represents a novel mechanism of action by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a crucial role in migraine pathophysiology. Clinical trials indicated that it significantly reduces the frequency and severity of migraine attacks compared to existing treatments. For millions of sufferers worldwide, this approval offers a new avenue for relief and highlights the importance of continued innovation in chronic pain management.Shifting gears to vaccine development, there's exciting progress in the fight against infectious diseases. A new vaccine candidate for malaria has shown an unprecedented level of efficacy in trial settings. This vaccine utilizes a protein-based approach that targets multiple stages of the parasite's lifecycle, thereby enhancing its protective effects. Given malaria's devastating impact globally, particularly in sub-Saharan Africa, this development is being hailed as a potential game-changer in global health efforts. As further studies and real-world evaluations unfold, this vaccine could become a cornerstone tool in reducing malaria's burden.Now turning our attention to industry trends, there's growing momentum around personalized medicine and its integration into mainstream healthcare systems. Personalized medicine tailors treatment strategies to individual patient profiles based on genetic, environmental, and lifestyle factors. Recent advances in genomics and data analytics have accelerated this shift, allowing for more precise and effective interventions. For healthcare providers and pharmaceutical companies alike, this trend necessitates rethinking traditional drug development models and embracing collaborative approaches to harness big data effectively.Finally, let's look at an intriguing development in neurodegenerative disease research. Scientists are exploring a new class of drugs designed to target protein misfolding—an underlying cause of conditions Support the show

Listen in as our expert panel discusses evidence-based approaches to help patients quit smoking, vaping, and using other nicotine products. You'll gain practical insights on medication selection, combination strategies, and tailored approaches for helping patients break free from nicotine addiction.Special guest:Robin Corelli, PharmD, CTTS, FCSHPProfessor of Clinical PharmacySchool of PharmacyUniversity of California, San FranciscoYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in November 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Smoking Cessation Drug TherapyFAQ: E-Cigarettes and VapingChart: Dos and Don'ts With PatchesArticle: Help Patients Send Their Vaping Habits Up in Smoke Use code mt1026 at checkout for 10% off a new or upgraded subscription.Send us a textEmail us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. Learn more about our product offerings at trchealthcare.com.

Sexy locations in WA Did you defy death? Piss in an elevator Clinical trials Albi learns about...the bodySee omnystudio.com/listener for privacy information.

Zain Johnson spoke to Clinical psychologist Dr Khosi Jiyani on the psychology behind why people drink and drive This programme is your authentic Cape Town wake-up call. Good Morning Cape Town with Lester Kiewit is informative, enlightening and accessible. The team’s ability to spot & share relevant and unusual stories make the programme inclusive and thought-provoking. Don’t miss the popular World View feature at 7:45am daily. Listen out for #LesterInYourLounge which is an outside broadcast – from the home of a listener in a different part of Cape Town - on the first Wednesday of every month. This show introduces you to interesting Capetonians as well as their favourite communities, habits, local personalities and neighbourhood news. Thank you for listening to a podcast from Good Morning Cape Town with Lester Kiewit. Listen live on Primedia+ weekdays between 06:00 and 09:00 (SA Time) to Good Morning CapeTalk with Lester Kiewit broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/xGkqLbT or find all the catch-up podcasts here https://buff.ly/f9Eeb7i Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

About 24.2% of U.S. men today screen positive for erectile dysfunction (ED), while global rates range from 3% to 76.5%, showing it's a common health problem that affects men of all ages A 2025 study in the American Journal of Clinical and Experimental Urology found that ED is influenced by genes that also raise risk for obesity, diabetes, heart disease, and addiction, tying erection problems to long-term heart health ED is usually multifactorial, with vascular, neurogenic, hormonal, and psychogenic forms, and is strongly associated with conditions like heart disease, obesity, sleep apnea, and depression, making it a powerful early warning sign that something deeper is wrong While drugs like Viagra can temporarily improve erections, they don't work for everyone and may be unsafe for men taking heart and lung medications Instead of relying solely on pills, addressing root causes with a heart-focused check-up, a metabolic-friendly diet, pelvic floor training, restorative sleep, enough sunlight and mindful supplementation can help restore sexual function without more drugs

Purely Clinical is more than an event; it's an experience where education meets innovation and the future of skincare takes shape.Over the past year, the Lira Clinical owners traveled across the globe delivering advanced education, protocol-driven learning, and exclusive first looks at upcoming innovations, straight to the treatment room. We're recapping standout moments from the tour stops and unpacking what attendees truly gained, from interactive sessions and protocol development to testing prototypes and influencing product launches before they hit the market.And of course, we're teasing what's ahead, because Purely Clinical 2026 is already shaping up to be something special. Join expert hosts and Lira Clinical founders Metaxia Dalikas and Francine Kagarakis for an inside look at the experience that's redefining clinical education.

Careful assessment and individualized care, provided by a skilled multidisciplinary care team, are emphasized in the holistic approach to neuropalliative care, which considers physical, psychological, social, spiritual, and existential aspects for people with neuromuscular diseases. In this episode, Gordon Smith, MD, FAAN, speaks with David J. Oliver, PhD, FRCP, FRCGP, FEAN, author of the article "Neuropalliative Care in Neuromuscular Disorders" in the Continuum® December 2025 Neuropalliative Care issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Oliver is an honorary professor of Tizard Centre at the University of Kent in Canterbury, United Kingdom. Additional Resources Read the article: Neuropalliative Care in Neuromuscular Disorders Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Smith: Hello, this is Dr Gordon Smith. Today I've got the great pleasure of interviewing Dr David Oliver about his article on neuropalliative care and neuromuscular disorders, which appears in the December 2025 Continuum issue on neuropalliative care. David, welcome to the Continuum podcast, and please introduce yourself to our audience. Dr Oliver: Thank you. It's a pleasure and a privilege to be here. I'm a retired consultant in palliative medicine in the UK. I worked at the Wisdom Hospice in Rochester for over thirty years, and I'm also an honorary professor at the University of Kent in Canterbury in the UK. I've had a long interest in palliative care in neurological diseases. Hopefully we can talk about a bit later. Dr Smith: I really look forward to learning a little bit more about your path and experiences. But I wonder if, before we get into the meat of neuropalliative care with a focus on neuromuscular, if maybe you can kind of set the stage by just defining palliative care. I mean, my experience is that people think of this in different ways, and a lot of folks think- hear palliative care, and they immediately go to end-of-life care or comfort care. So, what- how should we think about maybe the discipline of palliative care or neuropalliative care? Dr Oliver: I see palliative care as very much responding to people's needs, whether that's physical needs, psychological needs, social or spiritual or existential. So, it can be much earlier in the disease progression. And I think particularly for neurological diseases, early involvement may be very important. Dr Smith: That was actually going to be my first substantive question, really, was when to begin the conversation and what does that look like and how does it evolve over time. You have a really great figure in the article that kind of emphasizes the various stages within a patient's journey that, you know, palliative care can become involved. But I wonder if you could use ALS as a good example and describe what that looks like from when a patient is first diagnosed with ALS through their course? Dr Oliver: I think particularly in ALS at the beginning, soon after diagnosis, someone may have a lot of distress and a lot of questions that they need answering. This is a disease they've not had any contact with before. And they don't understand what's going on, they don't understand the disease. So, there may be a great need to have the opportunity to talk about the disease, what may happen, what is happening, how it's going to affect them and their family. As think time goes on, there may be later they develop swallowing problems, and that will need to be talking about a feeding tube and gastrostomy. And again, there may be a lot of issues for the person and their family. As they deteriorate, they may have respiratory problems and need to have discussion about ventilatory support, either by PAP, noninvasive ventilation, or even tracheostomy. And again, I think that's a big issue that needs wide discussion. And then it may be at the final few months of the disease, where they are deteriorating, that they may have increased needs, and their families may have those needs after the death. And I think often families bereaved from someone with a neurological disease such as ALS need a great deal of support, having many mixed emotions. There may be a feeling of relief that they're not involved in that caring, but then a feeling of guilt that they shouldn't be having those feelings. So, I think that can happen over a period of… what with ALS it may be two, three, four years, but it may be similar changes over time with any patient with a neurological disease. It may be ten or fifteen years with Parkinson's or five to ten years with a progressive supranuclear palsy, but there'll be this similar need to look at palliative care during their disease progression. Dr Smith: So, I'm curious at the time of diagnosis of ALS, how far out in the future do you provide information? So a specific question would be, do you talk about end-of-life management? In my experience, ALS patients are sometimes interested in knowing about that. Or do you really focus on what's in front of you in the next three to six months, for instance? Dr Oliver: I think it's both. Obviously, we need to talk about the next three to six months, but often giving patients the opportunity to talk about what's going to happen in the future, what may happen at the end of life, I think is important. And I think a disease like ALS, if they look it up on the Internet, they may have a lot of very distressing entries there. There's a lot about how distressing dying with ALS is. And actually confront those and discuss those issues early is really important. Dr Smith: So of course, the other thing that comes up immediately with an ALS diagnosis---or, for that matter, with any other neurodegenerative problem---is prognosis. Do you have guidance and how our listeners who are giving a diagnosis of ALS or similar disorder should approach the prognostication discussion? Dr Oliver: It's often very difficult. Certainly in the UK, people may have- be a year into their disease from their first symptoms before they're diagnosed, and I've seen figures, that's similar across the world. So, people may be actually quite way through their disease progression, but I do think we have to remember that the figures show that at five years, 25% of people are still alive, and 5 to 10% are still alive at ten years. We mustn't say you are going to die in the next two or three years, because that may not be so. And I think to have the vagueness but also the opportunity to talk, that we are talking of a deterioration over time and we don't know how that will be for you. I always stress how individual I think ALS is for patients. Dr Smith: One of the other concepts that is familiar with anyone who does ALS and clearly comes through in your article---which is really outstanding, by the way. So, thank you and congratulations for that---is the importance of multidisciplinary teams. Can you talk a little bit about how neuropalliative care sits within a multidisciplinary care model? Dr Oliver: I think the care should be multidisciplinary. Certainly in the UK, we recommended multidisciplinary team care for ALS in particular, from the time of diagnosis. And I think palliative care should be part of that multidisciplinary team. It may be a member of the team who has that palliative care experience or someone with specialist experience. Because I think the important thing is that everyone caring for someone with ALS or other neuromuscular diseases should be providing palliative care to some extent: listening to people, discussing their goals, managing their symptoms. And a specialist may only be needed if those are more complicated or particularly difficult. So, I think it is that the team needs to work together to support people and their families. So, looking at the physical aspects where the physiotherapist or occupational therapist may be very important, the psychologicals are a counsellor or psychologist. The social aspects, most of our patients are part of wider families, and we need to be looking at supporting their carers and within their family as well as the person. And so that may involve social work and other professionals. And the spiritual, the why me, their fears about the future, may involve a spiritual counsellor or a chaplain or, if appropriate, a religious leader appropriate to that- for that person. So, I think it is that wider care provided by the team. Dr Smith: I'm just reflecting on, again, your earlier answers about the Continuum of neuropalliative care. Knowing your patient is super valuable here. So, having come to know someone through their disease course must pay dividends as you get to some of these harder questions that come up later during the disease progression. Dr Oliver: I think that's the very important use of palliative care from early on in the diagnosis. It's much easier to talk about, perhaps, the existential fears of someone while they can still talk openly. To do that through a communication aid can be very difficult. To talk about someone's fear of death through a communication aid is really very, very difficult. The multidisciplinary team, I think, works well if all the members are talking together. So that perhaps the speech therapist has been to see someone and has noticed their breathing is more difficult, comes back and talks to the doctor and the physiotherapist. The social worker notices the speech is more difficult and comes back and speaks to the speech therapist. So, I think that sort of team where people are working very closely together can really optimize the care. And as you said, knowing the person, and for them to know you and to trust you, I think that's important. Those first times that people meet is so important in establishing trust. And if you only meet people when they're very disabled and perhaps not able to communicate very easily, that's really difficult. Dr Smith: I think you're reading my mind, actually, because I was really interested in talking about communication. And you mentioned a few times in your article about voice banking, which is likely to be a new concept for many of our listeners. And I would imagine the spectrum of tools that are becoming available for augmented communication for patients who have ALS or other disorders that impair speech must be impressive. I wonder if you could give us an update on what the state of the art is in terms of approaching communication. Dr Oliver: Well, I think we all remember Stephen Hawking, the professor from Cambridge, who had a very robotic voice which wasn't his. Now people may have their own voice on a communication aid. I think the use of whether it's a mobile phone or iPad, other computer systems, can actually turn what someone types into their own voice. And voice banking is much easier than it used to be. Only a few years ago, someone would have to read for an hour or two hours so the computer could pick up all the different aspects of their voice. Now it's a few minutes. And it has been even- I've known that people have taken their answer phone off a telephone and used that to produce a voice that is very, very near to the person. So that when someone does type out, the voice that comes out will be very similar to their own. I remember one video of someone who'd done this and they called their dog, and the dog just jumped into the air when he suddenly heard his master's voice for the first time in several months. So, I think it's very dramatic and very helpful for the person, who no longer feels a robot, but also for their family that can recognize their father, their husband, their wife's speech again. Dr Smith: Very humanizing, isn't it? Dr Oliver: There is a stigma of having the robotic voice. And if we can remove that stigma and someone can feel more normal, that would be our aim. Dr Smith: As you've alluded to, and for the large majority---really all of our ALS patients, barring something unexpected---we end up in preparing for death and preparing for end of life. I wonder what advice you have in that process, managing fear of death and working with our patients as they approach the end of their journey. Dr Oliver: I think the most important thing is listening and trying to find what their particular concerns are. And as I said earlier, they may have understood from what they've read in books or the Internet that the death from ALS is very distressing. However, I think we can say there are several studies now from various countries where people have looked at what happens at the end of life for people with ALS. Choking to death, being very distressed, are very, very rare if the symptoms are managed effectively beforehand, preparations are made so that perhaps medication can be given quickly if someone does develop some distress so that it doesn't become a distressing crisis. So, I think we can say that distress at the end of life with ALS is unusual, and probably no different to any other disease group. It's important to make sure that people realize that with good symptom control, with good palliative care, there is a very small risk of choking or of great distress at the end of life. Dr Smith: Now, I would imagine many patients have multiple different types of fear of death; one, process, what's the pain and experience going to be like? But there's also being dead, you know, fear of the end of life. And then this gets into comments you made earlier about spirituality and psychology. How do you- what's your experience in handling that? Because that's a harder problem, it seems, to really provide concrete advice about. Dr Oliver: Yeah. And so, I think it's always important to know when someone says they're frightened of the future, to check whether it is the dying process or after death. I've got no answer for what's going to happen afterwards, but I can listen to what someone may have in their past, their concerns, their experience. You know, is their experience of someone dying their memories of someone screaming in pain in an upstairs bedroom while they were a child? Was their grandfather died? Trying to find out what particular things may be really a problem to them and that we can try and address. But others, we can't answer what's going to happen after death. If someone is particularly wanting to look at that, I think that may be involving a spiritual advisor or their local spiritual/religious leader. But often I think it's just listening and understanding where they are. Dr Smith: So, you brought up bereavement earlier and you discussed it in the article. In my experience is that oftentimes the families are very, very impacted by the journey of ALS. And while ALS patients are remarkably resilient, it's a huge burden on family, loved ones, and their community. Can you talk a bit about the role of palliative care in the bereavement process, maybe preparing for bereavement and then after the loss of their loved one? Dr Oliver: Throughout the disease progression, we need to be supporting the carers as much as we are the patient. They are very much involved. As you said, the burden of care may be quite profound and very difficult for them. So, it's listening, supporting them, finding out what their particular concerns are. Are they frightened about what's going to happen at the end of life as well? Are they concerned of how they're going to cope or how the person's going to cope? And then after the death, it's allowing them to talk about what's happened and how they are feeling now, cause I think having had that enormous input in care, then suddenly everything stops. And also, the support systems they've had for perhaps months of the carers coming in, the doctor, the nurse, the physiotherapist, everyone coming in, they all stop coming. So, their whole social system suddenly stops and becomes much reduced. And I'm afraid certainly in the UK if someone is bereaved, they may not have the contact with their friends and family because they're afraid to come and see them. So, they may become quite isolated and reduced in what they can do. So, I think it's allowing them to discuss what has happened. And I think that's as important sometimes for members of the multidisciplinary team, because we as doctors, nurses and the wider team will also have some aspects of bereavement as we face not seeing that person who we've looked after for many years and perhaps in quite an intensive way. So, we need to be looking at how we support ourselves. And I think that's another important role of the multidisciplinary team. I always remember in our team, sometimes I would say, I find this person really difficult to cope with. And the rest of the people around the team would go have a sigh of relief because they felt the same, but they didn't like to say. And once we could talk about it, we could support each other and work out what we could do to help us help the patient in the most effective way. Dr Smith: Well, David, I think that's a great point to end on. I think you've done a really great job of capturing why someone would want to be a palliative care specialist or be involved in palliative care, because one of the themes throughout this conversation is the very significant personal and care impact that you have on patients and families. So, I really appreciate your sharing your wisdom. I really encourage all of our listeners to check out the article, it's really outstanding. I wonder if maybe you might just briefly tell us a little bit about how you got into this space? It's obviously one for which you have a great deal of passion and wisdom. How did you end up where you are? Dr Oliver: I became interested in palliative care as a medical student, and actually I trained as a family doctor, but I went to Saint Christopher's Hospice following that. I had actually had contact with them while I was a medical student, so I worked Saint Christopher's Hospice in South London when Dame Cecily Saunders was still working there. And at that time Christopher's had sixty-two beds, and at least eight of those beds were reserved for people with ALS or other neurological diseases. And I became very involved in one or two patients and their care. And Dame Sicily Saunders asked me to write something on ALS for their bookshelf that they had on the education area. So, I wrote, I think, four drafts. I went from sort of C minus to just about passable on the fourth draft. And that became my big interest in particularly ALS, and as time went on, in other neurological diseases. When I went to the Wisdom Hospice as a consultant, I was very keen to carry on looking after people with ALS, and we involved ourselves with other neurological patients. That's how I got started. Having that interest, listening to patients, documenting what we did became important as a way of showing how palliative care could have a big role in neurological disease. And over the years, I've been pressing again and again for the early involvement of palliative care in neurological diseases. And I think that is so important so that there can be a proper holistic assessment of people, that they can build up the trust in their carers and in the multidisciplinary team so that they can live as positively as possible. And as a result of that, that their death will be without distress and with their family with them. Dr Smith: Well, David, you've convinced and inspired me, and I'm confident you have our listeners as well. Thank you so much for a really informative, enjoyable, inspiring conversation. Dr Oliver: Thank you for inviting me. Dr Smith: Again, today I've been interviewing Dr David Oliver about his article on neuropalliative care and neuromuscular disorders, which appears in the December 2025 Continuum issue on neuropalliative care. Be sure to check out Continuum Audio episodes from this and other issues, and thanks to our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Healthcare CEO Vasanta Pundarika shares how behavioral health and women's health organizations can scale effectively while maintaining clinical mission and patient trust.

It's New Year's Eve Eve! Zach and Kevin return to close out the year with returning guests Dr. Gary Holtzclaw and Dr. Erin Elliott. In this final episode of 2025, the crew trades stories about their most memorable (and traumatic) New Year's Eve experiences—including a high school snowball fight that went terribly wrong and an intense dental school dodgeball tournament. Later, the conversation shifts from parties to protocols as the group discusses the major clinical and business changes they implemented in their practices this year. From AI integration and staffing shake-ups to battles with corporate CEOs and the rise of "Google Review extortion," they cover the highs and lows of practicing dentistry in 2025. Join the Very Clinical Facebook group!  Join the Very Dental Facebook Group using one of these passwords: Timmerman, Bioclear, Hornbrook, Gary, McWethy, Papa Randy, or Lipscomb!  The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! I'm a big fan of the Bioclear Method! I think you should give it a try and I've got a great offer to help you get on board! Use the exclusive Very Dental Podcast code VERYDENTAL8TON for 15% OFF your total Bioclear purchase, including Core Anterior and Posterior Four day courses, Black Triangle Certification, and all Bioclear products. Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code "VERYSHIP" you'll get free shipping on your order! Go save yourself some money and support the show all at the same time! The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!

JAMA Deputy Editor Mary McDermott, MD, and JAMA Deputy Editor Kristin Walter, MD, MS, highlight their selections of top JAMA Clinical Reviews podcasts in 2025. Related Content: Managing Adverse Effects of Obesity Medications Diagnosis and Management of Hypothyroidism Type 2 Diabetes: Diagnosis and Current Guidelines for Treatment Managing Adverse Effects of Incretin-Based Medications for Obesity Hypothyroidism Diagnosis and Treatment of Type 2 Diabetes in Adults JAMA Editors' Choice 2024: Clinical Reviews Podcasts

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com AI is finally eliminating the documentation burden that has slowed physicians for decades. In this episode, Dr. James Maisel, CEO and founder of ZyDoc, shares his three-decade journey from retina surgeon to health-tech entrepreneur and how AI is transforming clinical documentation. He reflects on early attempts to build electronic health records in the 1990s, the inefficiencies created by click-heavy systems, and why dictation consistently outperformed keyboard-based workflows. Dr. Maisel explains how advances in speech recognition and generative AI now make real-time, structured clinical notes possible, seamlessly integrating into EHRs and significantly reducing physician workload. He also explores health literacy challenges, physician adoption, specialty-specific language models, and the future of AI-driven diagnostics, particularly in the context of eye imaging. Tune in and learn how AI is reshaping clinical documentation, physician efficiency, and the future of medical practice! Resources: Connect with and follow Dr. James Maisel on LinkedIn. Follow ZyDoc on LinkedIn and visit their website!

In this episode, Dan Hackner, MD, Chief Clinical and Academic Officer, Southcoast Health, joins the podcast to discuss the role of concurrent data in improving clinical decision-making. He addresses gaps in educating and supporting caregivers, how health systems can anticipate the future affordability of care, and why deeply understanding community needs is essential to driving meaningful innovation in healthcare.

Glioblastoma has a long-term survival rate under 1% at ten years. After decades of research focusing primarily on mutation-targeted therapies, median survival has improved by only a few months. Dr. Tomás Duraj believes there's a better path forward.Dr. Duraj is a physician-scientist at Boston College working on the metabolic vulnerabilities of cancer. In this Metabolic Health Summit presentation, he outlines a clinical framework for studying ketogenic metabolic therapy — one built on biomarker-driven protocols, not dietary guesswork.The core argument: cancer cells depend on specific metabolic pathways for survival. Block those pathways while providing alternative fuels to healthy cells, and you create a therapeutic window that most tumors can't escape.Why cancer cells metabolically resemble organisms from 2 billion years agoThe limits of the somatic mutation theory and why most targeted gene therapies have underdeliveredSubstrate level phosphorylation vs. oxidative phosphorylation — and why the distinction mattersThe Glucose-Ketone Index as a measurable, actionable biomarkerThe press-pulse strategy: sustained metabolic pressure paired with targeted interventionsHow to protect healthy tissue before targeting tumor metabolismRepurposed pharmacological approaches and the need for publicly funded clinical trialsThe case for small, non-randomized pilot studies with highly motivated patientsMetabolic therapy represents the future of medicine: a coherent clinical strategy grounded in decades of research and increasingly recognized by physicians and scientists across disciplines. For practitioners seeking complementary approaches that extend the reach of oncological therapeutics, this presentation lays out a practical roadmap for integrating emerging insights with standard care.✅Genova Connect – Get 15% off any test kit with code METABOLICLINK here.✅ iRestore - Get a huge discount on the iRestore Illumina Face Mask when you use the code METABOLICLINK here.✅Piquelife.com - Get the Pu'er Bundle for 20% off here.In every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: Instagram Facebook YouTube LinkedIn Please keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

In this episode, our guest is Mary V. Relling, Pharm.D. Emerita Member, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Dr. Relling earned her undergraduate B.S. degree from the University of Arizona College of Pharmacy and her doctoral degree from the University of Utah College of Pharmacy. She completed post-doctoral fellowships with Dr. William Evans at St. Jude and with Dr. Urs Meyer at University of Basel. She joined St. Jude as a faculty member in 1988, and was chair ofthe Department of Pharmaceutical Sciences from 2003-2020. She was also a professor at the University of Tennessee in the Colleges of Medicine and Pharmacy. Her primary interests are in the treatment and pharmacogenetics of childhood leukemia and in the clinical implementation of pharmacogenetic testing in medicine. Dr. Relling is co-founder of CPIC, the Clinical Pharmacogenetics Implementation Consortium. She has published over 450 original scientific manuscripts. She was elected to the Institute of Medicine (National Academy of Medicine) in 2009.Topics to discuss:Foundations & Career JourneyYou've had an extraordinary career at St. Jude since joining in 1988. What first drew you to pediatric pharmacology and pharmacogenetics?Your work has helped shape how we treat childhood leukemia. What do you see as the most transformative advancements in this space over your career?Pharmacogenetics & CPICYou co-founded the Clinical Pharmacogenetics Implementation Consortium (CPIC). What was the impetus behind its creation, and how has its mission evolved?What do you see as the biggest barriers to widespread clinical implementation of pharmacogenetic testing today?How do you respond to skepticism about the clinical utility of pharmacogenetic testing in everyday medical practice?Which pharmacogenetic guidelines do you believe have had the most significant clinical impact so far—and why?What advice do you have for institutions that want to start implementing pharmacogenetic testing but don't know where to begin?Implementation in Clinical SettingsAt St. Jude, you helped lead efforts to integrate pharmacogenetic testing into clinical care. What lessons did you learn about operationalizing this work in real-world settings?How important is interdisciplinary collaboration—between pharmacists, physicians, geneticists—in making pharmacogenetic testing work in practice?Can you share an example where pharmacogenetic testing changed the course of treatment for a pediatric patient?Policy, Ethics, and Future VisionWhat policy or regulatory changes would help accelerate the clinical adoption of pharmacogenetic testing?As someone who has contributed extensively to the science, how do you think we should balance data privacy with the need for clinical data sharing in genomics?What are you most excited about in the future of pharmacogenetics? Are there particular therapeutic areas or technologies that you think will drive the next wave of innovation?Legacy & AdviceYou've mentored many rising leaders in the field. What qualities do you think are most important for the next generation of pharmacogenomics researchers and clinicians?With over 450 publications and a career that has changed pediatric pharmacology, what legacy do you hope your work leaves behind?Guest: Mary V. Relling, Pharm.D. Emerita Member, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research HospitalHost: Hillary Blackburn, PharmD, MBAwww.hillaryblackburn.comhttps://www.linkedin.com/in/hillary-blackburn-67a92421/  ★ Support this podcast on Patreon ★

In this episode of the Science of Skin podcast, Dr. Ted Lain and Dr. Andrew Alexis discuss Triferatine Cream, a novel fourth-generation retinoid. They explore its mechanism of action, clinical efficacy, and the importance of addressing not only acne lesions but also the psychosocial impacts of acne on patients. The conversation delves into the results of phase three and phase four clinical trials, highlighting Triferatine's effectiveness in treating both acne and post-inflammatory hyperpigmentation. The episode emphasizes the need for dermatologists to consider the entire acne journey and the long-term benefits of retinoid therapy for their patients. To watch this an other episodes, be sure to check out our YouTube page Takeaways: Triferatine is a novel fourth-generation retinoid. It binds preferentially to the RAR gamma receptor, enhancing its efficacy. Triferatine not only treats acne but also improves scarring and pigmentation. Clinical trials show significant efficacy in both facial and truncal acne. The psychosocial impact of acne is profound and long-lasting. Retinoids are foundational in acne treatment regimens. Patients benefit from continued use of retinoids beyond acne clearance. Phase four studies demonstrate Triferatine's effectiveness in reducing atrophic scars. Acne-induced hyperpigmentation is a significant concern that needs addressing. Education about retinoids can improve patient compliance.See omnystudio.com/listener for privacy information.

Dr. Timothy Spurrell—a fan favorite from Episode 7—is back for a powerful conversation on what truly sets great clinical leaders apart. In this episode, he shares practical insights, real-world lessons, and leadership perspectives that resonate with clinicians and executives alike.If you're looking for grounded wisdom, candor, and inspiration you can actually use in your healthcare environment, this is one episode you won't want to miss. Dr. Spurrell unpacks what great clinical leaders consistently do (and what they avoid), how strong leadership shows up in chaos and change, and the habits that build trust, accountability, and alignment across teams. You'll also hear practical ways to communicate with clarity and empathy—without lowering standards—and a refreshing reminder that great leadership isn't about charisma; it's about consistency.✨ Stay tuned for Part Two:  The Backbone, not the Face. It releases January 21, 2026 (you'll want the follow-up!)Guest: Dr. Timothy SpurrellHost: Amanda Laramie Book shoutouts in this episode:Will Guidara: Unreasonable Hospitality Thanks for listening! If you or someone you know should be interviewed for this show, send us an email. Check us out on: FacebookInstagramLinkedInOur WebsiteTikTokTwitterYouTube

Is science enough for total healing? Dr. Alex Lion and Dr. Anastasia Holman reveal how Spiritual Care in Healthcare is the secret to supporting clinical teams and patients in crisis. Modern medicine often focuses on the cure, but what happens when the goal is healing the whole person? In this episode of The Chaplain's Compass, hosts Rev. Alice Tremaine and Rev. John Betz explore the "Team-Based Spirituality" model. This revolutionary curriculum moves spiritual care out of the silo of the chaplaincy and integrates it into the daily workflow of physicians, nurses, and interprofessional teams. By analyzing the Havruta method of collaborative reflection and sharing case studies from pediatric neuro-oncology, our guests prove that spiritual care is a vital resource for preventing clinician burnout and navigating complex medical uncertainty. Whether you are a healthcare leader or a frontline provider, you will learn how to create inclusive spaces that honor every faith background—including atheism—to provide truly comprehensive care. Upcoming Workshop Meet the Speakers in New Orleans! Dr. Alex Lion and Reverend Dr. Anastasia Holman will be presenting a hands-on workshop on the Team-Based Spirituality Curriculum at the 2026 APC Conference. Don't miss this opportunity to learn how to scale spiritual care in your health system. Connect with Alice and John on social media: Instagram: @alicetremaine (Alice) @researchchaplain (John) https://www.linkedin.com/in/alicetremaine/ https://www.linkedin.com/in/chaplainbetz/ Leave us a message at the Chaplain's Compass phone number: 502-536-7508 Learn more about chaplaincy at https://www.chaplaincynow.com/ and the association of professional chaplains at https://www.apchaplains.org/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we dive into the latest breakthroughs and innovations shaping our industry. We start with a remarkable advancement in Alzheimer's disease treatment. A recent clinical trial has demonstrated significant progress in slowing cognitive decline among patients suffering from this challenging condition. The study, which involved a novel monoclonal antibody, showed promise by targeting amyloid plaques, a hallmark of Alzheimer's pathology. This approach not only opens new avenues for treatment but also provides hope for millions of patients and their families. The scientific community is closely monitoring these developments as they could redefine therapeutic strategies for neurodegenerative diseases.Moving on to regulatory news, the FDA has recently granted approval to a groundbreaking gene therapy for hemophilia B. This therapy represents a significant milestone as it offers a potential one-time treatment to correct the genetic defect underlying the disorder. By delivering a functional copy of the gene necessary for clotting factor production, patients may experience reduced bleeding episodes and improved quality of life. This approval underscores the FDA's commitment to advancing personalized medicine and highlights the transformative potential of gene therapies in addressing rare genetic conditions.In oncology, we've seen exciting progress with a novel targeted therapy showing efficacy in treating advanced stages of lung cancer. The drug specifically inhibits a mutation found in non-small cell lung cancer, which is often resistant to conventional treatments. Clinical trials have reported improved survival rates and better tolerability compared to existing therapies, marking a significant step forward in precision oncology. As researchers continue to unravel the complexities of cancer genomics, targeted therapies like this one offer new hope for patients battling aggressive forms of cancer.The biotech industry is also witnessing a surge in collaborations aimed at expediting vaccine development. In light of recent global health challenges, several companies have entered strategic partnerships to leverage their combined expertise in mRNA technology. These collaborations aim to accelerate the production and distribution of vaccines for infectious diseases beyond COVID-19. By pooling resources and sharing technological advancements, these alliances have the potential to enhance our preparedness for future pandemics and improve global public health outcomes.Shifting focus to autoimmune diseases, a novel small molecule inhibitor has shown potential in managing rheumatoid arthritis symptoms more effectively than traditional treatments. This new drug targets specific pathways involved in inflammation without compromising immune function. Early clinical data suggests it could offer patients relief with fewer side effects, representing a promising addition to the therapeutic arsenal against chronic inflammatory conditions.In an intriguing development within regenerative medicine, researchers have made strides in bioengineered organs. A recent breakthrough involves creating functional liver tissue from stem cells, paving the way for future organ transplantation solutions. These lab-grown tissues have demonstrated essential liver functions in preclinical models, bringing us closer to addressing organ shortages and enhancing transplant success rates. The implications of such advancements extend far beyond liver disease, offering transformative possibilities for regenerative therapies across various medical fields.Turning our attention to antimicrobial resistance, an ever-pressing concern within global health, scientists have discovered a new class of antibiotics capable of combating multidrug-resistant bacteria. This discovery comes atSupport the show

There's been a lot of focus lately on how much ‘screen time' children have and how technology is negatively impacting them. But scrolling on a cell phone all day is also terrible for adults. This is why many are making the case that both adults and children do a ‘digital detox' in 2026. Clinical psychologist and family therapist Dr. Sheryl Ziegler explains how damaging cell phones and social media have been for people of all ages, and offers tips on unplugging and improving mental health by avoiding the traps of modern tech. Then, we revisit one of our most impactful interviews from the past year, when Chairman of the House Intelligence Committee, Rep. Rick Crawford (AR-01) joined Mike Emanuel to react to President Trump's bold decision to bomb three Iranian nuclear sites this past June. Plus, commentary by Chuck DeVore, chief national initiatives officer with the Texas Public Policy Foundation. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Are you ready to feel grounded, energized, and confident in your wellness this year? Are you tired of starting January with restriction instead of nourishment? Do you want habits that actually stick and support your metabolism, hormones, and mental health? In this episode, Ali and Becki kick off the new year by sharing five foundational ways to invest in your wellness so your routines feel craveworthy, not forced. We discuss how pleasure, satisfaction, and real food are essential for sustainability, how to navigate cravings without shame, and why creating routines your body desires leads to lasting change. We also dive into supporting detox pathways, balancing blood sugar, and understanding how hormonal shifts—especially changes in estrogen—impact insulin sensitivity and metabolism as women age. Ali and Becki cover practical strategies for metabolic flexibility, the role of gratitude in nervous system and metabolic regulation, and why getting outside daily may be one of the most powerful (and overlooked) tools for stress resilience and healing.  Also in this episode:  Keto Reset Masterclass: 1/7/26 at 12pm CST  10-day Detox Masterclass: 1/5/26 at 12pm CST Keto Reset Program use code RESET75 Make your wellness craveworthy Super Greens Cubes FOND Bone Broth use code ALIMILLERRD Red Light Mask LumeBox Red Light use code BECKIYOO PEMF & Red Light Mat use code BeckiYoo10fs Addressing food cravings Naturally Nourished Episode 472 Good, Better, Best with Brenda … You Glow Girl Tea Support Your Detox Pathways E3 Live Beam Minerals Cellular Antiox Balance Your Blood Sugar The Role of Estrogen in Insulin Resistance: A Review of Clinical and Preclinical Data - ScienceDirect Naturally Nourished Episode 395 Testing Women's Hormones KetoMojo Nutrisense Practice Gratitude Naturally Nourished Episode 164 Make Positivity Louder and Keto … Work with Becki use code BECKIPACK for 10% off Get Outside Naturally Nourished Episode 424 How Daily Walking Can Transform … Naturally Nourished Episode 322 Nature as Medicine | Ali Miller RD Ali & Becki's Words for the Year Emerging Trends in the Wellness Space EMF Mitigation Aires Tech This episode is sponsored by the Naturally Nourished Food-as-Medicine Keto Reset. Our Keto Reset is a 12-week, real-food, functional medicine–based program designed to help you lower insulin, improve metabolic flexibility, and address the root causes behind stubborn weight loss, hormone imbalance, gut dysfunction, and chronic inflammation. Unlike traditional keto plans, this program focuses on macronutrient strategy over calorie obsession, antioxidant density, therapeutic foods, and high-quality sourcing—while eliminating ultra-processed foods and non-caloric sweeteners. The goal isn't restriction or perfection, but teaching your body how to burn fat efficiently while feeling nourished and supported. Throughout the program, you'll learn how to personalize your approach using sliding-scale protocols, understand how stress, hormones, and blood sugar influence metabolism, and build sustainable habits that lead to true food freedom. With weekly live classes, Q&As, and access to Ali and Becki's combined 20+ years of functional medicine experience, the Keto Reset is designed to work with your physiology—not against it—so you can finally feel confident, clear, and in control of your health. Join us now, use code RESET75 to save  

In this special series on Weight Bias and Stigma our host, Dr. Neil Skolnik will discuss weight bias and stigma and its importance because weight bias and stigma have an important impact  the experience of living with obesity, leads to measurable adverse outcomes, and when it is present in health care interactions it affects all subsequent care that a patient receives.. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Rebecca Pearl, PhD., Associate Professor, Director of Research, Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida Selected references: Weight stigma and bias: standards of care in overweight and obesity—2025. BMJ Open Diab Res Care 2025;13:e004962. doi:10.1136/ bmjdrc-2025-004962

There's been a lot of focus lately on how much ‘screen time' children have and how technology is negatively impacting them. But scrolling on a cell phone all day is also terrible for adults. This is why many are making the case that both adults and children do a ‘digital detox' in 2026. Clinical psychologist and family therapist Dr. Sheryl Ziegler explains how damaging cell phones and social media have been for people of all ages, and offers tips on unplugging and improving mental health by avoiding the traps of modern tech. Then, we revisit one of our most impactful interviews from the past year, when Chairman of the House Intelligence Committee, Rep. Rick Crawford (AR-01) joined Mike Emanuel to react to President Trump's bold decision to bomb three Iranian nuclear sites this past June. Plus, commentary by Chuck DeVore, chief national initiatives officer with the Texas Public Policy Foundation. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some fascinating breakthroughs and regulatory updates that are shaping the future of healthcare.Starting with a pivotal advancement in Alzheimer's research, a new drug has shown promising results in slowing cognitive decline in patients with early-stage Alzheimer's disease. This innovative therapy targets amyloid plaques in the brain, which are believed to play a central role in the progression of Alzheimer's. Recent clinical trials have demonstrated that patients receiving this treatment experienced a significant reduction in the rate of cognitive deterioration compared to those on a placebo. The implications of this development are profound, offering hope for millions affected by this debilitating condition. As researchers continue to unravel the mysteries of Alzheimer's, this breakthrough marks a crucial step forward in understanding and potentially halting disease progression.Moving on to regulatory news, the FDA has recently granted accelerated approval to a novel gene therapy for a rare genetic disorder known as spinal muscular atrophy (SMA). This condition, which affects motor neurons and leads to muscle wasting and weakness, primarily impacts infants and young children. The newly approved therapy works by delivering a functional copy of the defective gene directly into the patient's cells. Early trials have shown remarkable improvements in motor function and survival rates among treated infants. This approval represents not only a lifeline for affected families but also underscores the growing potential of gene therapies to address previously untreatable genetic diseases.In another significant development, researchers have unveiled a groundbreaking study on an experimental cancer vaccine that has demonstrated efficacy in preventing tumor growth in preclinical models. Unlike traditional vaccines aimed at infectious diseases, this cancer vaccine is designed to harness the body's immune system to specifically target and destroy cancer cells. The study's results indicate that the vaccine was successful in generating a robust immune response, which significantly inhibited tumor progression. If these findings can be replicated in human trials, it could open new avenues for cancer prevention and treatment, particularly for cancers with limited therapeutic options.Shifting our focus to trends within the industry, there's an increasing emphasis on personalized medicine, reflecting a broader shift towards treatments tailored to individual patients' genetic profiles. This approach aims to optimize therapeutic efficacy while minimizing adverse effects by considering each patient's unique genetic makeup. Advances in genomic sequencing technologies and bioinformatics are driving this transformation, enabling more precise diagnostics and targeted therapies. As personalized medicine continues to evolve, it holds the promise of revolutionizing how diseases are treated and managed in clinical practice.On the topic of drug approvals, a new oral medication for type 2 diabetes has received regulatory clearance after demonstrating superior glycemic control compared to existing treatments. This drug belongs to a novel class of medications that enhance insulin sensitivity and reduce glucose production by targeting specific metabolic pathways. Clinical trials indicated significant improvements in blood sugar levels and overall metabolic health among participants. Given the global prevalence of type 2 diabetes and its associated health complications, such advancements are crucial for improving patient outcomes and reducing healthcare burdens.Lastly, focusing on collaborations within the industry, several prominent pharmaceutical companies have announced partnerships aimed at accelerating research in infectious diseases.Support the show

There's been a lot of focus lately on how much ‘screen time' children have and how technology is negatively impacting them. But scrolling on a cell phone all day is also terrible for adults. This is why many are making the case that both adults and children do a ‘digital detox' in 2026. Clinical psychologist and family therapist Dr. Sheryl Ziegler explains how damaging cell phones and social media have been for people of all ages, and offers tips on unplugging and improving mental health by avoiding the traps of modern tech. Then, we revisit one of our most impactful interviews from the past year, when Chairman of the House Intelligence Committee, Rep. Rick Crawford (AR-01) joined Mike Emanuel to react to President Trump's bold decision to bomb three Iranian nuclear sites this past June. Plus, commentary by Chuck DeVore, chief national initiatives officer with the Texas Public Policy Foundation. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us a textAs 2025 comes to a close, Ben and Daphna reflect on a year of growth, community, and evolution for The Incubator Podcast. In this end-of-year wrap-up, they preview major changes coming in 2026, including new standalone podcast feeds, expanded journal club content, CME opportunities, and exciting partnerships with organizations like the Vermont Oxford Network and PAS. They also share what's ahead for the Delphi Conference and offer a candid look at their personal and professional goals for the year ahead. Thank you for being part of this extraordinary neonatal community. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

What if one case manager guided both the surrogate and the intended parents—from the first profile exchange to baby photos years later? We sit down with Nina Simmons, case manager and clinical support manager at Northwest Surrogacy Center, to explore how a unified model reduces miscommunication, deepens trust, and creates a steadier surrogacy journey. Nina pulls back the curtain on the real work behind the scenes: coordinating clinics and legal timelines, keeping everyone informed, and offering trauma-informed support when emotions run high.We talk about the head-and-heart balance that keeps a match on track: the administrative structure that provides safety and the relational care that builds confidence. Nina shares practical ways to set expectations early, from communication preferences to boundary setting, and explains how transparent group conversations help resolve friction before it grows. She also addresses common challenges—loss of control for intended parents, boundary fatigue for surrogates—and shows how predictability and clear options restore a sense of agency. IVF is powerful but not absolute; offering choice, clarity, and steady presence helps everyone breathe through the unknowns.You'll also hear how the pandemic reshaped matching and support—Zoom meetings, online groups, and a renewed desire for in-person connection—and why ethical guardrails matter when choosing an agency. Nina's guidance on vetting compensation packages, reading the fine print on lost wages and insurance, and understanding state-by-state legal pathways is essential listening for anyone considering surrogacy. If you're searching for a model that honors both people and process, this conversation delivers practical insights and real hope.If the conversation resonates, follow the show, share it with someone who needs it, and leave a quick review to help others find honest, human-centered surrogacy stories.Send us a texthttps://stopsitsurrogate.com

Calling out "Happy Christmas to all and to all a good-night,  Dr. Griffin and Vincent Racaniello discuss high path influenza in dairy herds in Wisconsin and Marburg virus in Ethiopia before Dr. Griffin then deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, the slightly higher association of COVID-19 infection with death than following influenza infection, benefit of passive infant immunization with niresevimab, association of COVID-19 vaccine immunogenicity protection against severe disease in vulnerable populations, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, effect of remdesivir and nirmatrelvir/ritonavir on COVID-19 associated mortality, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode USDA Confirms Highly Pathogenic Avian Influenza in a Dairy Herd in Wisconsin (USDA Animal and Plant Health Inspection Service) Update: Genetic Sequencing Results for Wisconsin Dairy Herd Detection of Highly Pathogenic Avian Influenza(USDA Animal and Plant Health Inspection Service) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles(CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) In call with clinicians, CDC recommends flu vaccines widely(CIDRAP) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) Increased 30-day Mortality Risk in Coronavirus Disease 2019 Compared to Seasonal Influenza (International Journal of Infectious Diseases) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns (JAMA) RSV Immunization Frequently Asked Questions(American Academy of Pediatrics) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Association between COVID-19 vaccine immunogenicity and protection against infection and severe disease in clinically vulnerable patient populations: a systematic review and meta-analysis of observational studies (Clinical Microbiology and Infection) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trial (Clinical Microbiology and Infection) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Long-COVID research just got a big funding boost: will it find new treatments? (Nature) Reaching out to US house representative Letters read on TWiV 1282 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Dyane Tower to Dean's Chat. This episode is sponsored by the American Podiatric Medical Association (APMA)! Dyane Tower, DPM, MPH, MS, CAE is a nationally recognized leader in podiatric medicine and healthcare administration, currently serving as Medical Director and Vice President of Clinical Affairs for the American Podiatric Medical Association (APMA). With a unique blend of clinical training and executive leadership, Dr. Tower plays a pivotal role in shaping national clinical policy, professional standards, and advocacy efforts for the podiatric profession. She holds the degrees of Doctor of Podiatric Medicine degree from the Scholl College of Podiatric Medicine, and completed her 3 year residency at the North Coloroado Podiatric Medicine Surgery program. Her background highlights advanced expertise in organizational governance, strategy, and healthcare leadership. Her interdisciplinary background allows her to bridge clinical practice, public health, and national-level professional advocacy. At APMA, Dr. Tower oversees: • Clinical policy and professional practice standards • Clinical education and evidence-based guidelines • Regulatory affairs and federal advocacy • Public health integration and interdisciplinary collaboration Dr. Tower is widely respected for her strategic vision, clarity of communication, and deep commitment to advancing podiatric medicine at a national level. As a featured guest on Dean's Chat, she provides expert insight into healthcare policy, clinical governance, professional advocacy, and the future direction of the podiatric profession. Beyond her executive leadership, Dr. Tower is known for her mentorship, national speaking engagements, and ongoing efforts to elevate the voice and visibility of podiatric physicians within the broader healthcare ecosystem. Enjoy!

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Clinical Advances and Unanswered Questions in Narcolepsy," Lindsay McCullough, MD, discusses how clinical understanding of narcolepsy has evolved, where major diagnostic and treatment advances have occurred, and where important gaps remain. McCullough, assistant professor of medicine and associate program director for the sleep medicine fellowship at Rush University, reflects on progress in defining narcolepsy subtypes, the growing role of orexin biology, and how recent research in 2025 has reshaped conversations around disease-modifying approaches. The discussion also explores emerging links between sleep disorders and neurodegenerative disease, common misconceptions that continue to delay diagnosis, and how clinician education can improve recognition, safety, and long-term management of patients with narcolepsy. Looking for more Sleep Disorder discussion? Check out the NeurologyLive® Sleep Disorder clinical focus page. Episode Breakdown: 1:05 – Advances and remaining gaps in the clinical understanding of narcolepsy 2:30 – How narcolepsy care and research meaningfully evolved throughout 2025 4:50 – Sleep disorders, neurodegeneration, and what clinicians should watch for 6:50 – Neurology News Minute 8:50 – Persistent myths that delay diagnosis and affect clinical decision-making 12:30 – How lived experience shapes holistic, patient-centered narcolepsy care The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Endocrine Surgery emergencies are rare. However, they can be clinically significant and understanding how to navigate them as a surgeon in timely fashion is critical. Hosts:  Dr. Rebecca Sippel is an endowed professor of surgery and Division Chief of Endocrine Surgery at University of Wisconsin (UW) - Madison, and she is the most recent past president of the American Association of Endocrine Surgeons (AAES).  She is an internationally recognized leader in the field of endocrine surgery with over 250 publications. She was the principal investigator for a hallmark randomized controlled trial which studied the need for prophylactic central neck dissections in thyroid cancer.   Dr. Amanda Doubleday is a fellowship trained endocrine surgeon in private practice with an affiliation to UW Health. Her primary practice is with Waukesha Surgical Specialists in Waukesha WI. Her clinical interests are in robotic adrenalectomy, benign and malignant thyroid cancer and hyperparathyroidism. Dr. Simon Holoubek is a fellowship trained endocrine surgeon affiliated with UW Health. His primary practice is with UW Health with privileges at UW Madison and UW Northern Illinois. His clinical interests are aggressive variants of thyroid cancer, parathyroid autofluorescence, and nerve monitoring.  Learning Objectives: 1) Learn about thyroid storm in hyperthyroidism and treatment options. 2) Understand how to treat hypercalcemic crisis due to uncontrolled primary hyperparathyroidism. 3) Describe the modified surgical techniques required for thyroidectomy in patients with Graves' disease to prevent recurrent laryngeal nerve traction injury. 4) Identify clinical and intraoperative indicators of parathyroid carcinoma and explain the necessity of en bloc resection to prevent parathyromatosis. References: 1 Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: A meta-analysis. J Surg Res. 2000 May 15;90(2):161-5. doi: 10.1006/jsre.2000.5875. PMID: 10792958. https://pubmed.ncbi.nlm.nih.gov/10792958/ 2 Yoshimura Noh J, Inoue K, Suzuki N, Yoshihara A, Fukushita M, Matsumoto M, Imai H, Hiruma S, Ichikawa M, Koshibu M, Sankoda A, Hirose R, Watanabe N, Sugino K, Ito K. Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil. Endocr J. 2024 Jul 12;71(7):695-703. doi: 10.1507/endocrj.EJ24-0135. Epub 2024 May 3. PMID: 38710619. https://pubmed.ncbi.nlm.nih.gov/38710619/ 3 Christopher L, Mellman M, Buicko JL. Management of Hypercalcemic Crisis due to Primary Hyperparathyroidism During Pregnancy. Am Surg. 2023 Aug;89(8):3638-3640. doi: 10.1177/00031348231162704. Epub 2023 Apr 27. PMID: 37102502. https://pubmed.ncbi.nlm.nih.gov/37102502/ Sponsor Disclaimer: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Visionary vs. Integrator: The Two Types of Cash-Practice Entrepreneurs Clique away long enough and you lose your patient's attention. That's why Claire, our AI scribe built specifically for physical therapists, handles the documentation so you can focus on the person in front of you. Try it free at MeetClaire.ai. In this episode of the PT Entrepreneur Podcast, Dr. Danny breaks down two personality types that show up again and again inside cash-based practices: the Visionary and the Integrator. He explains why knowing your type gives you an immediate advantage, how it shapes your strengths, and which weaknesses can hold you back from scaling. What You'll Learn The difference between Visionaries and Integrators in a cash practice Why founders naturally lean toward one role—and how to spot yours Where each style excels (and where they struggle) Why early-stage entrepreneurs must build skills outside their comfort zone Two books that can change your trajectory depending on your type How to build momentum by pairing effort with accuracy Recommended Books For Integrators: How to Win Friends and Influence People For Visionaries: The Checklist Manifesto Key Takeaways Your natural wiring is an advantage—once you understand it. Visionaries need structure, systems, follow-through, and consistency. Integrators must learn the people-facing skills that drive business early on. Business growth accelerates when you focus effort on the right skills at the right time. You don't need more broad information—you need targeted learning and repetition. Want Personalized Guidance? If you want help identifying your strengths, gaps, and the clearest path to grow your cash practice, book a free call with a PT Biz senior advisor:

Send us a textTransitioning from fellowship to your first attending job? You're probably not prepared for the business side of medicine—and that's exactly the problem Dr. Tung Giep addresses in this episode. Dr. Giep, a neonatologist with over 30 years of experience, shares hard-earned lessons from building and selling a private practice in Houston, navigating toxic work environments, and eventually finding his place in telemedicine. His new book, The Business of Medicine: The Definitive Guide to Help New Physicians Start Their Career on the Right Path and Avoid Costly Mistakes, tackles what medical training ignores: contract negotiation, non-competes, choosing the right CPA and attorney, and understanding your self-worth.Ben and Dr. Giep discuss why new physicians get blindsided by job offers, how to vet a practice properly, and the reality of community neonatology versus academic medicine. They also explore the growing role of AI in healthcare and what it means for the next generation of physicians. Whether you're finishing fellowship or reconsidering your current position, this conversation offers practical guidance on taking control of your career—and avoiding costly mistakes along the way. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this episode, Nathan A. Merriman, MD, MSCE, Interim Senior Medical Director of Surgical Specialties for the Digestive Health Clinical Program at Intermountain Medical Center, discusses how a patient-centered, team-based approach can improve access to care while enhancing the overall human experience. He shares insights on driving operational efficiency across surgical services and aligning clinical teams to deliver high-quality, coordinated care that meets patients where they are.

This episode breaks down the major misconceptions about ADHD treatment and clarifies what decades of research, major clinical guidelines, and leading experts actually recommend. Ryan and Mike explain why weekly talk therapy is not an evidence-based treatment for ADHD, why parent training and environmental structure are consistently shown to improve outcomes, and how parents can make informed decisions without getting pulled into common myths.Find Mike @ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.grownowadhd.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ & on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠IG⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Ryan @ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.adhddude.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ & on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube{{chapters}}[00:00:00] Start[00:02:21] What clinical guidelines actually recommend[00:05:27] Dr. Barkley's research on effective ADHD treatments[00:09:11] Evidence on CBT, DBT, and play therapy[00:19:21] Why office-based therapy doesn't translate to real-world behavior[00:22:29] Rumination and how talk-heavy approaches can backfire[00:31:19] Treatments with the strongest evidence (medication, parent training)⁠⁠⁠Citations:1. AAP Guideline (Parent Training + Medication as First-Line)Wolraich, M. L., et al. (2019). Clinical practice guideline for ADHD in children and adolescents. Pediatrics, 144(4), e20192528.2. AACAP Treatment Parameter (Medication + Behavioral)Pliszka, S. R., & AACAP Work Group. (2007). Practice parameter for ADHD. JAACAP, 46(7), 894–921.3. Barkley: ADHD as Performance DisorderBarkley, R. A. (2012). Executive functions. Guilford Press.Barkley, R. A. (2015). ADHD: Handbook for diagnosis and treatment (4th ed.). Guilford Press.4. CBT Evidence (Adolescents/Adults, Not Young Children)Safren, S. A., et al. (2010). CBT vs relaxation for adults with ADHD. JAMA, 304(8), 875–880.Solanto, M. V. (2011). CBT for adult ADHD. Guilford Press.Langberg, J. M., et al. (2008). Organization skills intervention for adolescents. JCCP, 76(6), 967–982.5. DBT-Informed (Pilot Trials, Emotion Dysregulation)Murray, D. W., et al. (2022). DBT skills group for adolescents with ADHD. J Attention Disorders, 26(11), 1421–1430.6. Play Therapy (Insufficient Evidence)Hassan, R. A., & Shaker, N. S. (2014). CBPT for ADHD symptoms. Int J Psychology & Behavioral Sciences, 4(6), 221–229.7. EF Skills: Experience-Based, Not Language-BasedBarkley, R. A. (2012). Executive functions. Guilford Press.8. Rumination and ADHDOstojic, D., et al. (2021). Mind wandering and rumination in youth with ADHD. J Abnormal Child Psychology, 49, 1203–1216.Seymour, K. E., et al. (2014). Emotion regulation mediates ADHD-depression relationship. J Abnormal Child Psychology, 42, 611–621.9. Time Blindness/Temporal ProcessingToplak, M. E., & Tannock, R. (2005). Time perception deficits in ADHD. J Abnormal Child Psychology, 33(5), 639–654.Barkley, R. A., et al. (2008). ADHD in adults: What the science says. Guilford Press.10. Parent Behavior Training (Evidence-Based)Chronis, A. M., et al. (2006). Evidence-based treatments for children with ADHD. Clinical Psychology Review, 26(4), 486–502.Evans, S. W., et al. (2014). Evidence-based treatments for ADHD. JCCAP, 43(4), 527–551.11. Medication as First-LineFaraone, S. V., et al. (2021). Stimulant effectiveness and safety. World Psychiatry, 20(3), 314–329.Swanson, J. M., et al. (2017). MTA study long-term outcomes. JAACAP, 56(3), 228–240.

Join hosts Zach and Kevin for the annual Very Clinical holiday wrap-up! This week, they welcome back the recurring year-end duo, Dr. Erin Elliott and Dr. Gary Holtzclaw. It is officially a tradition as Erin and Gary join the guys to break down how they are spending the holidays and what has changed in their lives over the last twelve months. In this festive episode, the group shares their unique Christmas traditions, ranging from Icelandic rice pudding games to seafood feasts and tongue-in-cheek "virgin sacrifices." Beyond the holiday cheer, they dive into significant life updates. Kevin discusses the transition of selling his practice to become an associate and his growing obsession with pickleball. Erin shares the joys of empty nesting and her quest to visit every NFL stadium. Gary reveals why he deleted his social media accounts to reclaim his attention span and his commitment to taking real vacations, while Zach opens up about the realities of taking over full ownership of his family practice. It is a candid look at the personal and professional evolution of four dentists at different stages of their careers. Join the Very Clinical Facebook group!  Join the Very Dental Facebook Group using one of these passwords: Timmerman, Bioclear, Hornbrook, Gary, McWethy, Papa Randy, or Lipscomb!  The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! I'm a big fan of the Bioclear Method! I think you should give it a try and I've got a great offer to help you get on board! Use the exclusive Very Dental Podcast code VERYDENTAL8TON for 15% OFF your total Bioclear purchase, including Core Anterior and Posterior Four day courses, Black Triangle Certification, and all Bioclear products. Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code "VERYSHIP" you'll get free shipping on your order! Go save yourself some money and support the show all at the same time! The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!

Parenting and addiction are not two words you want in the same sentence, but unfortunately, addiction happens, and thus, parents need to know the facts about it. The Inherited Pattern of Addiction Addiction isn't just about individual choices; it often stems from generational patterns and dysfunction. Many people facing addiction today can trace their struggles back to influences and events in their family history. The interplay of epigenetics and unresolved emotional issues can shape how children are raised and how they handle challenges, impacting their potential for addiction. Recognizing Warning Signs in Children Parents might wonder what the early indicators of their child's potential addiction could be. It's essential to pay attention to changes in behavior, such as shifts in interests, friend groups, or academic performance. Unexplained isolation, carrying certain items everywhere, or noticeable changes in physical appearance can also signal underlying issues. Always trust your instincts; if you suspect something, there's often a valid reason behind it. The Role of Anxiety and Emotional Neglect Balancing Boundaries with Understanding Handling Older Children and Adult Addiction Relapse During the Holiday Season Holidays can amplify stressors, leading to a spike in relapses. Increased pressure, financial strain, and family dynamics can overwhelm someone in recovery. Families can support their loved ones by keeping celebrations manageable and straightforward, and avoiding substances that might trigger a relapse. Planning and open discussions about expectations can alleviate holiday-induced anxiety, helping maintain sobriety. Faith as a Pillar in Recovery About Kim Castro Kim Castro is committed to helping individuals, families, treatment programs, and addiction counselors develop and grow. She utilizes cutting-edge treatment modalities to deliver a gold standard of clinical care. For over a decade, Kim was the Executive Director of Recovery Outfitters, Inc. Kim is a certified master's-level counselor and certified clinical supervisor who instructs counselors seeking or maintaining credentials. She earned a master's degree in Conflict Management and a bachelor's degree in psychology from Kennesaw State University. Kim is recognized as a Subject Matter Expert in the field of addiction, even helping to revise the international master's-level certification for addiction counseling. In addition, she integrates both Faith-based and Clinical approaches to addiction treatment. Website for Kim Castro Read the full show notes and access all links. Additional Resources Download Kim's Guide on Helping vs. Enabling Book Recommendation: Boundaries by Dr. Henry Cloud and Dr. John Townsend

Clinical psychologist, educational leader, and author of Untethered: Creating Connected Families, Schools and Communities to Raise a Resilient Generation, Dr. Doug Bolton, joins me this week to unpack the rising levels of anxiety, burnout, and overwhelm we're seeing in kids today.   Together we explore:   - How changes in education starting in the 90s have intensified academic pressure for kids of all ages. - Why school avoidance, perfectionism, and burnout are rising, even among high-achieving students. - The neuroscience behind why rigor, overscheduling, and constant output make it harder for kids to access curiosity, regulation, and real learning. - How expectations have shifted, and why many kids simply aren't developmentally ready for what schools now demand. - Realistic, achievable ways to build rest, connection, and resilience into daily family life. - Small shifts parents can make at home to buffer their child's stress, protect their mental health, and restore balance.   If your child is melting down after school, anxious about grades, overwhelmed by homework, or feeling weighed down by pressure to perform, this episode will help you understand what's really going on beneath the surface and give you practical tools to support their wellbeing.     LEARN MORE ABOUT MY GUEST:

This episode, recorded live at the 10th Annual. Health IT + Digital Health + RCM Annual Meeting features Dr. Brian Patterson, Physician Administrative Director for Clinical AI, UW Health, who shares where AI is delivering real impact today in revenue cycle and clinical workflows and offers guidance on deploying AI responsibly amid rapid innovation and evolving governance.

In this episode, Coach Debbie Potts sits down with Dr. Zulia Frost, Co-Founder and Medical Director of Recharge Health, to explore how targeted red light therapy can support mitochondrial repair, thyroid function, gut health, liver detoxification, and overall metabolic resilience for adults navigating midlife. If you are in your 40s, 50s, 60s, or beyond and want to improve your energy, metabolism, hormone balance, digestion, and recovery, this conversation provides the education, tools, and strategies you need to optimize your health from the inside out. Zulia explains the science behind photobiomodulation, how red and near-infrared light activate cellular energy pathways, and why FlexBeam delivers medical-grade targeted therapy directly to organs and tissues that need it most. We break down the research on mitochondrial function, Hashimoto's and thyroid hormone conversion, gut inflammation, motility challenges, liver congestion, stress recovery, and active aging. This episode is especially relevant for midlife athletes, high performers, over-40 adults experiencing metabolic slowdown, and anyone wanting to age with strength, clarity, and vitality. Mentioned in the Episode FlexBeam by Recharge Health Try FlexBeam and save with code: CoachDebbiePotts Website: https://recharge.health (affiliate support is appreciated) Topics Covered • Why mitochondrial function declines with age and how red light supports ATP production • The connection between photobiomodulation and thyroid hormone activation • Clinical research on PBM for Hashimoto's and autoimmune thyroid dysfunction • Red light therapy for gut inflammation, motility, and microbiome balance • Liver detoxification, metabolic health, and targeted PBM application • Supporting the nervous system, vagal tone, sleep quality, and stress recovery • FlexBeam protocols for midlife athletes and active aging • How to integrate daily PBM routines into lifestyle, training, and recovery • Why targeted photobiomodulation works differently from full-body light panels About Zulia Frost Dr. Zulia Frost is a pioneer in photobiomodulation, neuromuscular rehabilitation, and integrative medicine. With more than two decades of clinical experience, she is internationally recognized for her work in cellular repair technologies and her scientific leadership at Recharge Health. Connect with Coach Debbie Potts Website: https://www.debbiepotts.net Podcast: The Coach Debbie Potts Show YouTube: https://www.youtube.com/@coachdebbiepotts Instagram: @coachdebbiepotts Email: coachdebbiepotts@icloud.com Support the Show If this episode helped you understand how to age stronger instead of slower, please rate, review, and share it with someone looking to improve their health, metabolism, and longevity.

In this episode of the MaternalRX podcast on the Pharmacy Podcast Network, Danielle sits down with Dr. Tadeh Vartanian, a Pharmacist and Medical Lead with deep expertise in autoimmune diabetes. Drawing on years of clinical practice and research, Dr. Vartanian explains why early detection and precise diabetes classification can dramatically shift outcomes for people who are pregnant, planning pregnancy, or managing complex metabolic risks. This conversation delivers a practical, up-to-date overview of diabetes types, maternal risk considerations, screening strategies, and the emerging science behind autoimmune and genetic diabetes. And if you have never heard of monogenic diabetes, you will want to hear this episode! Understanding this category can immediately change how clinicians diagnose and treat patients. Diabetes types explained - How to differentiate type 1 diabetes, type 2 diabetes, gestational diabetes, and monogenic diabetes - Why type 1 is autoimmune and what loss of 80 to 90 percent of beta cells means for patient management - The phases of type 1 diabetes and the predictive power of autoantibodies - How monogenic diabetes presents differently and when to consider genetic testing - Which diabetes types can improve with targeted lifestyle interventions Diabetes screening and diagnostic testing - Why early screening is the most impactful action clinicians can take - When to use hemoglobin A1C, fasting glucose, and the oral glucose tolerance test - A clear explanation of the 50-gram and 100-gram Glucola tests used in gestational diabetes screening and diagnosis - How to identify autoimmune diabetes using autoantibody testing Autoantibody screening programs - TrialNet: the NIDDK-supported program offering at-home screening for people with a first-degree relative with type 1 diabetes - ASK (Autoimmunity Screening for Kids): now expanded to adults, with nationwide access through the University of Colorado laboratory - How these programs detect autoimmune diabetes before symptoms develop Genetics, autoimmunity, and diabetes research - How new genetic testing is reshaping the identification of monogenic diabetes - What autoimmune activity means in type 1 diabetes and why early detection matters - Current research, evolving guidelines, and clinical trial insights relevant to maternal health and diabetes care Diabetes and pregnancy - How diabetes influences pregnancy outcomes and why classification accuracy is critical - The long-term significance of gestational diabetes and its link to future type 2 diabetes - Clinical considerations for preconception counseling, prenatal care, and postpartum metabolic health - How maternal diabetes affects the long-term health trajectory of both parent and child Key takeaway from Dr. Vartanian: Screen early and use the right tools. Identifying diabetes risk before symptoms appear can change the course of care at every stage of pregnancy. Connect with our guest and host: - Dr. Tadeh Vartanian: www.linkedin.com/in/tadehvartanian/ - Dr. Danielle Plummer: www.linkedin.com/in/daniellerplummer/

In this episode, Anthony J. Tortolani, MD, FACS, FACC, Cardiac and Thoracic Surgeon and Professor Emeritus of Clinical Cardiothoracic Surgery at Weill Cornell Medical College, discusses the realities of declining profit margins and how leaders are balancing financial pressures with clinical excellence. He explores practical applications of AI in clinical medicine, including improvements in efficiency and less invasive surgical approaches, and shares why aligning strategic vision with day-to-day tactical planning is essential for long-term success in cardiovascular care.

Welcome to "Labor & Delivery Debrief," the podcast where we tackle your toughest questions about childbirth and maternal health. Today, we're diving deep into a fascinating and critical topic sent in by one of our listeners, Sarah. Sarah asks: "Is it possible for a clinical diagnosis of chorioamnionitis to not be confirmed by placental histology? And if so, how is that possible?" This is a fantastic question that touches on the complexities of intrapartum clinical diagnosis of intraamniotic infection (IAI), also commonly known as chorioamnionitis. We'll explore the nuances of clinical versus histological findings, the diagnostic criteria, and why these two assessments don't always perfectly align. Get ready for a detailed discussion that will shed light on this important aspect of obstetric care.1. ACOG CO 712; 2017 (2025)2. Romero R, Pacora P, Kusanovic JP, et al. Clinical Chorioamnionitis at Term X: Microbiology, Clinical Signs, Placental Pathology, and Neonatal Bacteremia - Implications for Clinical Care. Journal of Perinatal Medicine. 2021;49(3):275-298. doi:10.1515/jpm-2020-0297.3. Jung E, Romero R, Suksai M, et al. Clinical Chorioamnionitis at Term: Definition, Pathogenesis, Microbiology, Diagnosis, and Treatment. AJOG. 2024;230(3S):S807-S840. doi:10.1016/j.ajog.2023.02.002.4. Oh KJ, Kim SM, Hong JS, et al. Twenty-Four Percent of Patients With Clinical Chorioamnionitis in Preterm Gestations Have No Evidence Of either Culture-Proven Intraamniotic Infection Or intraamniotic Inflammation. AJOG. 2017;216(6):604.e1-604.e11.